Inventor · disambiguated record
Annette Atkins
Also filed as: ATKINS ANNETTE · ATKINS ANNETTE R
19 granted patents·19 pending applications·37 citations·filing 2014–2023
92Inventor score
Files withSALK INST FOR BIOLOGICAL STUDI38
Top patents by PatentIndex Score
38 records- 0192US11685901B2Compositions and methods for organoid generation and disease modelingSALK INST FOR BIOLOGICAL STUDI·Filed 2022·Granted Jun 27, 2023·1 cites·19 claims
- 0292US11376264B2Use of bromodomain-containing protein 9 antagonists in combination with vitamin D receptor agonists in diabetes treatmentSALK INST FOR BIOLOGICAL STUDI·Filed 2020·Granted Jul 5, 2022·3 cites·18 claims
- 0392US10301268B2Analogs of fexaramine and methods of making and usingSALK INST FOR BIOLOGICAL STUDI·Filed 2016·Granted May 28, 2019·4 cites·31 claims
- 0489US9546379B2Compositions and methods for treating type 1 and type 2 diabetes and related disordersSALK INST FOR BIOLOGICAL STUDI·Filed 2015·Granted Jan 17, 2017·7 cites·4 claims
- 0586US10920199B2Reprogramming progenitor compositions and methods of use thereforeSALK INST FOR BIOLOGICAL STUDI·Filed 2016·Granted Feb 16, 2021·4 cites·14 claims
- 0686US10912800B2Compositions and methods for treating type 1 and type 2 diabetes and related disordersSALK INST FOR BIOLOGICAL STUDI·Filed 2016·Granted Feb 9, 2021·5 cites·19 claims
- 0786US9925241B2Mutated fibroblast growth factor (FGF) 1 and methods of useSALK INST FOR BIOLOGICAL STUDI·Filed 2014·Granted Mar 27, 2018·6 cites·15 claims
- 0882US9925243B2Chimeric fibroblast growth factor (FGF) 2/FGF1 peptides and methods of useSALK INST FOR BIOLOGICAL STUDI·Filed 2016·Granted Mar 27, 2018·5 cites·32 claims
- 0980US2024101962A1Compositions and methods for organoid generation and disease modelingSALK INST FOR BIOLOGICAL STUDI·Filed 2023·Application pending·0 cites
- 1077US10695404B2Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogsSALK INST FOR BIOLOGICAL STUDI·Filed 2018·Granted Jun 30, 2020·1 cites·28 claims
- 1175US12253527B2Compositions and methods for treating age-related diabetes and related disordersSALK INST FOR BIOLOGICAL STUDI·Filed 2022·Granted Mar 18, 2025·0 cites·16 claims
- 1275US11428697B2Compositions and methods for treating age-related diabetes and related disordersSALK INST FOR BIOLOGICAL STUDI·Filed 2019·Granted Aug 30, 2022·0 cites·8 claims
- 1373US12213999B2Compositions and methods for treating type 1 and type 2 diabetes and related disordersSALK INST FOR BIOLOGICAL STUDI·Filed 2021·Granted Feb 4, 2025·0 cites·20 claims
- 1473US11440889B2Analogs of fexaramine and methods of making and usingSALK INST FOR BIOLOGICAL STUDI·Filed 2020·Granted Sep 13, 2022·0 cites·20 claims
- 1573US10539572B2Compositions and methods for treating age-related diabetes and related disordersSALK INST FOR BIOLOGICAL STUDI·Filed 2016·Granted Jan 21, 2020·1 cites·15 claims
- 1671US10815203B2Analogs of fexaramine and methods of making and usingSALK INST FOR BIOLOGICAL STUDI·Filed 2019·Granted Oct 27, 2020·0 cites·20 claims
- 1768US2020040051A1Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucoseSALK INST FOR BIOLOGICAL STUDI·Filed 2019·Application pending·0 cites
- 1867US2023097335A1Fibroblast growth factor 1 (fgf1) mutant proteins that selectively activate fgfr1b to reduce blood glucoseSALK INST FOR BIOLOGICAL STUDI·Filed 2022·Application pending·0 cites
- 1966US10450277B2Analogs of fexaramine and methods of making and usingSALK INST FOR BIOLOGICAL STUDI·Filed 2018·Granted Oct 22, 2019·0 cites·18 claims
- 2065US11760977B2Compositions and methods for organoid generation and disease modelingSALK INST FOR BIOLOGICAL STUDI·Filed 2017·Granted Sep 19, 2023·0 cites·16 claims
- 2162US11981931B2Reprogramming progenitor compositions and methods of use thereofSALK INST FOR BIOLOGICAL STUDI·Filed 2020·Granted May 14, 2024·0 cites·20 claims
- 2262US11542309B2Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucoseSALK INST FOR BIOLOGICAL STUDI·Filed 2020·Granted Jan 3, 2023·0 cites·20 claims
- 2359US2025082781A1Methods of lowering blood glucose and treating type 2 diabetes by activation of pde4d3SALK INST FOR BIOLOGICAL STUDI·Filed 2022·Application pending·0 cites
- 2458US2019192630A1Mutated fibroblast growth factor (fgf) 1 and methods of useSALK INST FOR BIOLOGICAL STUDI·Filed 2019·Application pending·0 cites
- 2558US2017355740A1Methods of using fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods to reduce blood glucoseSALK INST FOR BIOLOGICAL STUDI·Filed 2017·Application pending·0 cites
- 2656US2018193418A1Mutated fibroblast growth factor (fgf) 1 and methods of useSALK INST FOR BIOLOGICAL STUDI·Filed 2018·Application pending·0 cites
- 2753US2021363490A1Cells, islets, and organoids that evade immune detection and autoimmunity, methods of production and use thereofSALK INST FOR BIOLOGICAL STUDI·Filed 2019·Application pending·0 cites
- 2851US2017355739A1Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucoseSALK INST FOR BIOLOGICAL STUDI·Filed 2017·Application pending·0 cites
- 2949US2019276510A1Use of fibroblast growth factor 1 (fgf1)-vagus nerve targeting chimeric proteins to treat hyperglycemiaSALK INST FOR BIOLOGICAL STUDI·Filed 2019·Application pending·0 cites
- 3048US2018207114A1ESTROGEN RELATED RECEPTOR GAMMA (ERRgamma) ENHANCES AND MAINTAINS BROWN FAT THERMOGENIC CAPACITYSALK INST FOR BIOLOGICAL STUDI·Filed 2018·Application pending·0 cites
- 3148US2019151416A1Fibroblast growth factor (fgf) 1 proteins with glucose lowering ability and reduced mitogenicitySALK INST FOR BIOLOGICAL STUDI·Filed 2019·Application pending·0 cites
- 3247US2018057554A1Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucoseSALK INST FOR BIOLOGICAL STUDI·Filed 2017·Application pending·0 cites
- 3346US2017291931A1Fgf2 truncations and mutants and uses thereofSALK INST FOR BIOLOGICAL STUDI·Filed 2017·Application pending·0 cites
- 3445US2018000768A1Intestinal fxr agonism enhances glp-1 signaling to restore pancreatic beta cell functionsSALK INST FOR BIOLOGICAL STUDI·Filed 2017·Application pending·0 cites
- 3544US2018319857A1Fgf2 truncations and mutants and uses thereofSALK INST FOR BIOLOGICAL STUDI·Filed 2018·Application pending·0 cites
- 3642US2018015057A1Err alpha and err gamma are essential coordinators of cardiac metabolism and functionSALK INST FOR BIOLOGICAL STUDI·Filed 2017·Application pending·0 cites
- 3739US2015258052A1Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissueSALK INST FOR BIOLOGICAL STUDI·Filed 2015·Application pending·0 cites
- 3838US2016237133A1Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of useSALK INST FOR BIOLOGICAL STUDI·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Annette Atkins files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →